Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of the corrected count increment after platelet transfusion, a secondary analysis of the PACER randomized controlled trial.
van Baarle FLF, van de Weerdt EK, van der Velden WJFM, Ruiterkamp RA, Tuinman PR, Ypma PF, van den Bergh WM, Demandt AMP, Kerver ED, Jansen AJG, Westerweel PE, Arbous MS, Determann RM, van Mook WNKA, Koeman M, Mäkelburg ABU, van Lienden KP, Vlaar APJ, Biemond BJ. van Baarle FLF, et al. Among authors: westerweel pe. Am J Hematol. 2023 Nov;98(11):E305-E308. doi: 10.1002/ajh.27053. Epub 2023 Aug 21. Am J Hematol. 2023. PMID: 37605361 Free article. No abstract available.
Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia.
van Baarle FLF, van de Weerdt EK, van der Velden WJFM, Ruiterkamp RA, Tuinman PR, Ypma PF, van den Bergh WM, Demandt AMP, Kerver ED, Jansen AJG, Westerweel PE, Arbous SM, Determann RM, van Mook WNKA, Koeman M, Mäkelburg ABU, van Lienden KP, Binnekade JM, Biemond BJ, Vlaar APJ. van Baarle FLF, et al. Among authors: westerweel pe. N Engl J Med. 2023 May 25;388(21):1956-1965. doi: 10.1056/NEJMoa2214322. N Engl J Med. 2023. PMID: 37224197 Clinical Trial.
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
Bistervels IM, Buchmüller A, Wiegers HMG, Ní Áinle F, Tardy B, Donnelly J, Verhamme P, Jacobsen AF, Hansen AT, Rodger MA, DeSancho MT, Shmakov RG, van Es N, Prins MH, Chauleur C, Middeldorp S; Highlow Block writing committee; Highlow Investigators. Bistervels IM, et al. Lancet. 2022 Nov 19;400(10365):1777-1787. doi: 10.1016/S0140-6736(22)02128-6. Epub 2022 Oct 28. Lancet. 2022. PMID: 36354038 Clinical Trial.
Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial.
Hamulyák EN, Wiegers HMG, Hutten BA, de Lange ME, Timmermans A, Westerweel PE, Nijziel MR, Klok FA, Hovens MM, Kamphuisen PW, Büller HR, Middeldorp S, Scheres LJJ. Hamulyák EN, et al. Among authors: westerweel pe. Res Pract Thromb Haemost. 2024 May 20;8(4):102448. doi: 10.1016/j.rpth.2024.102448. eCollection 2024 May. Res Pract Thromb Haemost. 2024. PMID: 38953049 Free PMC article. No abstract available.
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL.
Hengeveld PJ, Kolijn PM, Demmers JAA, Doff W, Dubois JMN, Rijken M, Assmann JLJC, van der Straten L, Boiten HJ, Gussinklo KJ, Valk PJM, Faber LM, Westerweel PE, Kater AP, Levin MD, Langerak AW. Hengeveld PJ, et al. Among authors: westerweel pe. Hemasphere. 2023 Sep 15;7(10):e951. doi: 10.1097/HS9.0000000000000951. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37731707 Free PMC article.
The upper extremity postthrombotic syndrome score: an international Delphi consensus study to determine the score's functional disability component.
Schropp L, Cats RB, de Kleijn RJCMF, van Hattum ES, Middeldorp S, Nijkeuter M, Westerink J, Petri BJ, de Borst GJ; Upper Extremity PTS group. Schropp L, et al. Res Pract Thromb Haemost. 2023 Jan 19;7(1):100051. doi: 10.1016/j.rpth.2023.100051. eCollection 2023 Jan. Res Pract Thromb Haemost. 2023. PMID: 36873563 Free PMC article.
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Huls G, Chitu DA, Tick L, Boersma R, Breems D, Herbers A, Klein SK, de Jonge S, Westerweel PE, Cruijsen M, Hoogendoorn M, Cuijpers M, Deeren D, Bailly B, Visser O, van Rhenen A, Posthuma EFM, Valk PJM, Cloos J, Ammatuna E, Refos JM, Fakkert R, Löwenberg B, Ossenkoppele GJ. Huls G, et al. Among authors: westerweel pe. Ann Hematol. 2024 Oct 5. doi: 10.1007/s00277-024-06033-y. Online ahead of print. Ann Hematol. 2024. PMID: 39367118
109 results